# OnCo record nct06435429 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06435429/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06435429", "NCT06435429" ;
  schema:name "A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o"@en ;
  schema:description "A phase 3 trial of Zanidatamab, Trastuzumab, Eribulin in her2-positive breast cancer, run by Jazz Pharmaceuticals, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06435429/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06435429> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-08-13" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/eribulin/>, <https://onco.cc/drugs/vinorelbine/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:companies <https://onco.cc/companies/jazz/> .